This page contains a Flash digital edition of a book.
estradiol +/- norethisterone


A non-equine product range to meet the needs of your HRT patients


1 Elleste is indicated for hormone replacement


therapy (HRT) for oestrogen deficiency symptoms in post or peri-menopausal women


UK/ELL/16/0002b Date of preparation: January 2016


estradiol hemihydrate 1 mg and 2 mg respectively. Elleste SoloTM transdermal patch containing 1.25 mg estradiol hemihydrate and Elleste SoloTM


ELLESTE (estradiol +/- norethisterone acetate). PRESCRIBING INFORMATION. PRESENTATION: Elleste SoloTM


hemihydrate and 1 mg norethisterone acetate. INDICATION: Hormone replacement therapy for oestrogen deficiency symptoms in peri- and post-menopausal women (Elleste SoloTM


in post-menopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis (Elleste DuetTM SoloTM


tablets: One tablet daily in hysterectomised women; in women with an intact uterus, progestogen should be added for 12-14 days each cycle. Elleste SoloTM 80 patch: initiate treatment with Elleste SoloTM


DOSAGE AND ADMINISTRATION: Elleste SoloTM


symptoms. If menstruating regularly, start within five days of bleeding. See SmPC for details of switching from other forms of HRT. Apply one patch twice weekly; in women with an intact uterus, progestogen should be added for 12-14 days during each cycle. The dosage may be increased by using Elleste SoloTM


CONTRA-INDICATIONS: Pregnancy or breastfeeding. Known, past or suspected breast cancer. Known or suspected oestrogen-dependent malignant tumours. Undiagnosed genital bleeding.


thrombophlebitis. Previous idiopathic or current venous thromboembolism. Known thrombophilic disorders. Active or recent arterial thromboembolic disease. Acute liver


Untreated endometrial hyperplasia. Active


followed by one grey tablet taken daily for 12 days, then begin a new cycle without a break. Elleste DuetTM


1 mg film-coated tablets: One white tablet taken daily for 16 days followed by one pale green tablet taken daily for 12 days, then begin a new cycle without a break. Elleste DuetTM


2 mg film-coated tablets: One orange tablet taken daily for 16 days Conti: One tablet taken daily.


MX 80. Elleste Duet MX 40 in women with menopausal


1 mg and 2 mg film-coated MX 40 and


MX 80 patch). Conti; Elleste DuetTM 2 mg; Elleste SoloTM 2 mg; Elleste


MX 40 patch) and in post-menopausal women with an intact uterus who are at least one year post menopause (Elleste DuetTM


Conti). Prevention of osteoporosis ; Elleste DuetTM


(orange tablets) and estradiol hemihydrate 2 mg and norethisterone acetate 1 mg (grey tablets). Elleste DuetTM


; Elleste SoloTM


80 mcg Transdermal Patch containing 2.5 mg estradiol hemihydrate and delivers 40 and 80 micrograms of estradiol respectively per 24 hours. Elleste DuetTM 1 mg film-coated tablets containing estradiol hemihydrate 1 mg (white tablets) and estradiol hemihydrate 1 mg and norethisterone acetate 1 mg (pale green tablets). Elleste DuetTM


2 mg film-coated tablets containing estradiol hemihydrate 2 mg Conti film-coated tablets containing 2 mg estradiol


1 mg and 2 mg film-coated tablets containing MX 40 mcg MX


disease or history of liver disease as long as LFTs are abnormal. Dubin-Johnson or Rotor Syndromes. Hypersensitivity to the active substances or excipients. Porphyria. WARNINGS AND PRECAUTIONS: HRT should only be initiated for symptoms that adversely affect quality of life. In all cases, a careful appraisal of the risks and benefits should be undertaken at least annually. HRT should only be continued as long as the benefit outweighs the risk. Before initiating or reinstituting HRT, take a complete personal and family medical history and perform appropriate physical examinations. Advise women about what breast changes should be reported. Closely supervise women with the following conditions or a history of them: leiomyoma or endometriosis; history of, or risk factors for, thromboembolic disease; risk factors for oestrogen dependent tumours; hypertension; liver disorders; diabetes mellitus; cholelithiasis; migraine or severe headache; systemic lupus erythematosus; endometrial hyperplasia; epilepsy; asthma; otosclerosis. Discontinue therapy if a contraindication is discovered and in the following conditions: hepatitis, jaundice or deteriorating liver function; significant increase in blood pressure; sudden severe chest pain; sudden breathlessness; unexplained swelling or pain in calf; severe stomach pain; prolonged immobility after surgery or leg injury; new onset migraine-type headache; pregnancy. Risk of endometrial hyperplasia and carcinoma are increased when oestrogens are administered alone for prolonged periods. The risk is reduced with the addition of a progestogen for at least 12 days per cycle in non-hysterectomised women. Investigate breakthrough bleeding. An increased risk of breast cancer has been reported that is dependent on the length of treatment. HRT can increase the density of mammographic images which may affect radiological detection of breast cancer. HRT is associated with an increased relative risk of venous thromboembolism (VTE) or pulmonary embolism (PE). Risk factors include personal or family history of thrombosis, severe obesity, systemic lupus erythematosus, immobilisation, major trauma and major surgery. Consider discontinuing HRT 4-6 weeks before elective surgery requiring immobilisation. Therapy should be discontinued if VTE develops after initiating surgery. There is an increased risk of cardiovascular morbidity during the first year of use of HRT. HRT is associated with an up to 1.5 fold increased risk of stroke. Long term use of oestrogens in hysterectomised women has been associated with an increased risk of ovarian cancer. Oestrogens may cause fluid retention. Women with pre-existing hypertriglyceridemia should be followed closely (risk of pancreatitis). Certain endocrine tests may be affected. No evidence for improvement in cognitive function. Increased risk of gallbladder disease. Liver tumours leading to intra-abdominal haemorrhage have been reported. Patients with rare hereditary disorders of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Elleste Duet


2 mg film-coated tablets and Elleste Solo 2 mg film-coated tablets contain sunset yellow colouring (E110) which can cause allergic reactions. May interact with other medicines. See SmPC for potential interactions. SIDE EFFECTS: Common side effects (>1/100): Erythema, itching; uterine bleeding; breast tenderness and enlargement; increase in size of uterine fibroids; nausea; abdominal pain; headache; weight increase / decrease; oedema; change in mood including anxiety and depressive mood; change in libido. Other side effects include: Vaginal candidiasis; vomiting; gallbladder disease; pancreatitis, gallstones; dizziness; migraine; increased blood pressure; leg cramps; alopecia; hirsutism; rash; itching; venous thromboembolism; thrombophlebitis; thrombosis; endometrial neoplasia; dysmenorrhoea; aggravation of endometriosis; changes in cervical eversion, production of mucus and erosion; cystitis-like syndrome; endometrial cancer; breast cancer; bloating; myocardial infarction; stroke; liver tumours; cholestatic jaundice; chloasma; erythema multiforme; erythema nodosum; muscle cramps; vascular purpura; steepening of corneal curvature; visual disturbances; intolerance to contact lenses; sodium and water retention; reduced glucose tolerance; aggravation of porphyria and probable dementia. See SmPC for all side effects. MARKETING AUTHORISATION NUMBERS AND COST: 1 mg: PL15142/0061; 3 x 28 film-coated tablets £5.06. Elleste SoloTM PL15142/0062; 3 x 28 film-coated tablets £5.06. Elleste SoloTM PL15142/0060; 8 patches £5.19. Elleste SoloTM 8 patches £5.99. Elleste DuetTM £9.20. Elleste DuetTM DuetTM


Conti: PL15142/0065; 3 x 28 film-coated tablets £17.02. MARKETING AUTHORISATION HOLDER: Meda Pharmaceuticals Ltd. Further information is available on request from: Meda Pharmaceuticals Ltd., Skyway House, Parsonage Road, Takeley, Bishop’s Stortford CM22 6PU. Tel. 0845 4600000. Date of preparation: November 2015. UK/ELL/14/0003(1)


REFERENCE: 1. Elleste Summary of Product Characteristics (2015), Meda Pharmaceuticals Ltd.


Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to


Meda’s Medical Information line on 01748 828810. 2 mg: PL15142/0064; 3 x 28 film-coated tablets £9.20. Elleste 1 mg: PL15142/0063; 3 x 28 film-coated tablets MX 80 mcg: PL15142/0059;


Elleste SoloTM 2 mg:


MX 40 mcg:


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108